Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiovascular Disease
FDA approves Lipitor to lower risk of heart attacks
September 5th, 2004
Pfizer, Inc., reported the U.S. Food and Drug Administration (FDA) has approved its cholesterol-lowering therapy Lipitor (atorvastatin calcium) for the prevention of cardiovascular disease by reducing heart attack risk in people with normal-to-mildly elevated cholesterol levels who have other cardiovascular risk factors. The FDA's decision was based on the findings of the ASCOT trial (Anglo-Scandinavian cardiac outcomes trial), which found that the lowest dose of Lipitor (10 mg) reduced the relative risk of heart attack by 36% compared to placebo. Because these significant benefits were seen so early, the trial was ended nearly 2 years ahead of schedule. ...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
